Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Vertex Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 09:40PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, I cover the biotechnology sector at Goldman Sachs, and we're really pleased to have Vertex team with us today. So we have Reshma Kewalramani, who's the CEO and the President, as well as Stuart Arbuckle, who's the Chief Operating Officer of the company.

Thank you both for joining us.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

To start here, maybe we could give a snapshot of the business, where it stands today, what we should anticipate in terms of strategy, commercial execution and the pipeline as we look towards the second half of the year and beyond?

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Sounds great. Well, first of all, it's very nice to see all of you in person as we are still all getting back to in-person meetings. Let me say a few words about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot